NeoGenomics Inc. (NEO)
NeoGenomics Statistics
Share Statistics
NeoGenomics has 128.66M shares outstanding. The number of shares has increased by 0.59% in one year.
Shares Outstanding | 128.66M |
Shares Change (YoY) | 0.59% |
Shares Change (QoQ) | 0.08% |
Owned by Institutions (%) | 96.83% |
Shares Floating | 127.12M |
Failed to Deliver (FTD) Shares | 204 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.84M, so 3.77% of the outstanding shares have been sold short.
Short Interest | 4.84M |
Short % of Shares Out | 3.77% |
Short % of Float | 5.22% |
Short Ratio (days to cover) | 3.34 |
Valuation Ratios
The PE ratio is -26.51 and the forward PE ratio is 27.26. NeoGenomics's PEG ratio is 2.32.
PE Ratio | -26.51 |
Forward PE | 27.26 |
PS Ratio | 3.16 |
Forward PS | 1.2 |
PB Ratio | 2.31 |
P/FCF Ratio | -61.32 |
PEG Ratio | 2.32 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for NeoGenomics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.98, with a Debt / Equity ratio of 0.67.
Current Ratio | 1.98 |
Quick Ratio | 1.89 |
Debt / Equity | 0.67 |
Debt / EBITDA | -400.62 |
Debt / FCF | -17.78 |
Interest Coverage | -13.92 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $300.26K |
Profits Per Employee | $-35.78K |
Employee Count | 2,200 |
Asset Turnover | 0.4 |
Inventory Turnover | 13.85 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -30.72% in the last 52 weeks. The beta is 1.41, so NeoGenomics's price volatility has been higher than the market average.
Beta | 1.41 |
52-Week Price Change | -30.72% |
50-Day Moving Average | 10.44 |
200-Day Moving Average | 14.25 |
Relative Strength Index (RSI) | 48.48 |
Average Volume (20 Days) | 1.42M |
Income Statement
In the last 12 months, NeoGenomics had revenue of 660.57M and earned -78.73M in profits. Earnings per share was -0.62.
Revenue | 660.57M |
Gross Profit | 290.1M |
Operating Income | -92.11M |
Net Income | -78.73M |
EBITDA | -1.51M |
EBIT | -74.06M |
Earnings Per Share (EPS) | -0.62 |
Balance Sheet
The company has 367.01M in cash and 605.33M in debt, giving a net cash position of -238.32M.
Cash & Cash Equivalents | 367.01M |
Total Debt | 605.33M |
Net Cash | -238.32M |
Retained Earnings | -325.78M |
Total Assets | 1.64B |
Working Capital | 294.78M |
Cash Flow
In the last 12 months, operating cash flow was 7.02M and capital expenditures -41.06M, giving a free cash flow of -34.04M.
Operating Cash Flow | 7.02M |
Capital Expenditures | -41.06M |
Free Cash Flow | -34.04M |
FCF Per Share | -0.27 |
Margins
Gross margin is 43.92%, with operating and profit margins of -13.94% and -11.92%.
Gross Margin | 43.92% |
Operating Margin | -13.94% |
Pretax Margin | -11.92% |
Profit Margin | -11.92% |
EBITDA Margin | -0.23% |
EBIT Margin | -13.94% |
FCF Margin | -5.15% |
Dividends & Yields
NEO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for NEO is $18.5, which is 93.9% higher than the current price. The consensus rating is "Buy".
Price Target | $18.5 |
Price Target Difference | 93.9% |
Analyst Consensus | Buy |
Analyst Count | 10 |
Stock Splits
The last stock split was on Apr 16, 2003. It was a backward split with a ratio of 1:100.
Last Split Date | Apr 16, 2003 |
Split Type | backward |
Split Ratio | 1:100 |
Scores
Altman Z-Score | 1.45 |
Piotroski F-Score | 4 |